Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $12.00 and last traded at $12.09, with a volume of 884288 shares. The stock had previously closed at $12.73.
Wall Street Analysts Forecast Growth
BAYRY has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their target price on shares of Bayer Aktiengesellschaft from €75.00 ($76.53) to €80.00 ($81.63) and gave the stock an “overweight” rating in a research note on Wednesday, August 31st. Deutsche Bank Aktiengesellschaft upped their target price on shares of Bayer Aktiengesellschaft from €75.00 ($76.53) to €79.00 ($80.61) and gave the stock a “buy” rating in a research note on Tuesday, August 16th. Exane BNP Paribas upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “outperform” rating in a research note on Tuesday, August 30th. Finally, Morgan Stanley reduced their target price on shares of Bayer Aktiengesellschaft from €87.00 ($88.78) to €80.00 ($81.63) and set an “overweight” rating for the company in a research note on Wednesday, September 7th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.00.
Bayer Aktiengesellschaft Stock Performance
The company has a market cap of $47.51 billion, a P/E ratio of 5.88, a price-to-earnings-growth ratio of 1.09 and a beta of 1.09. The company’s 50-day moving average is $13.65 and its two-hundred day moving average is $15.49. The company has a quick ratio of 0.84, a current ratio of 1.18 and a debt-to-equity ratio of 1.00.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
- Get a free copy of the StockNews.com research report on Bayer Aktiengesellschaft (BAYRY)
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.